A rare clinical case: treatment of a mediastinal tumor without organospecificity

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The incidence of malignant neoplasms is steadily increasing every year. In addition to common localizations, oncologists encounter non-standard tumors that require a personalized approach to treatment depending on the clinical situation. In recent decades, there has been significant progress in the creation of pharmacological drugs that are successfully used in the treatment of cancer, which selectively affect various targets in tumor cells. The article presents a clinical case of diagnosis and treatment of an anterior mediastinal tumor without organospecificity. An effective option for drug therapy aimed at targets found in tumor cells is described. The presented example demonstrates an individualized approach to the choice of treatment for a cancer patient and the effectiveness of its use.

Texto integral

Acesso é fechado

Sobre autores

Yaroslavna Yakimenko

Astrakhan State Medical University; Regional Clinical Oncology Dispensary

Autor responsável pela correspondência
Email: maleeva.yaroslavna@yandex.ru
ORCID ID: 0000-0002-2276-2562
Código SPIN: 7642-6150

Postgraduate Student, Department of Oncology and Radiation Therapy, Astrakhan State Medical University

Rússia, Astrakhan; Astrakhan

V. Kutukov

Astrakhan State Medical University; Regional Clinical Oncology Dispensary

Email: maleeva.yaroslavna@yandex.ru
ORCID ID: 0000-0002-8167-2997
Rússia, Astrakhan; Astrakhan

S. Gavrilova

Regional Clinical Oncology Dispensary

Email: maleeva.yaroslavna@yandex.ru
ORCID ID: 0009-0004-7602-1243
Rússia, Astrakhan

K. Rotar

Astrakhan State Medical University

Email: maleeva.yaroslavna@yandex.ru
ORCID ID: 0009-0000-9522-9665
Rússia, Astrakhan

Bibliografia

  1. Li B., Chan H. L., Chen P. Immune checkpoint inhibitors: basics and challenges. Curr Med Chem. 2019;26(17):3009–3025. doi: 10.2174/0929867324666170804143706.
  2. Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801. doi: 10.1038/s41467-020-17670-y.
  3. Gunturi A., McDermott D. F. Nivolumab for the treatment of cancer. Expert Opin Investig Drugs. 2015;24(2):253–260. doi: 10.1517/13543784.2015.991819.
  4. Sundar R., Cho B. C., Brahmer J.R., Soo R. A. Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7(2):85–96. doi: 10.1177/1758834014567470.
  5. Darvin P., Toor S. M., Sasidharan Nair V., Elkord, E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12): 1–11. doi: 10.1038/s12276-018-0191-1.
  6. de Miguel M., Calvo E. Clinical challenges of immune checkpoint inhibitors. Cancer Cell. 2020;8(3):326–333. doi: 10.1016/j.ccell.2020.07.004.
  7. Shiravand Y., Khodadadi F., Kashani S.M.A., et al. Immune checkpoint inhibitors in cancer therapy. Current Oncol. 2022;29(5):3044–3060. doi: 10.3390/curroncol29050247.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Bionika Media, 2024